- Nachrichtendetail
-
09.07.2024 06:59:58 - dpa-AFX: EQS-Adhoc: Basel, 9th July 2024 Matthias Schupp appointed as CEO of Medartis (english)
Basel, 9th July 2024 Matthias Schupp appointed as CEO of Medartis
PRESS RELEASE
Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is
solely responsible for the content of this announcement.
Medartis today announced that its Board has appointed Matthias Schupp to the
position of CEO, joining Medartis by the beginning of November. Matthias
will succeed Christoph Brönnimann, who will ensure a seamless transition.
Matthias brings excellent knowledge of the global medical technology sector,
having held various senior leadership roles in Europe and Latin America at
Straumann Group over the last 17 years. During his tenure at Straumann, he
demonstrated a strong ability to perform and transform. In 2014, he assumed
the post of SVP of LATAM at Straumann and in 2015 he also became CEO of
Neodent, steering the LATAM region through ten years of significant growth
and enabling Neodent to flourish into a leading global challenger brand. He
was appointed to the Executive Management Board of Straumann in 2016.
Matthias began his career in 1986 with Merck KGaA and rose through country
management to the position of Regional Manager Latin America and USA. He
moved to Wella in 2000 as Managing Director of the business in Russia and
became Managing Director Professional Care Portugal in 2004, following the
acquisition of Wella by P&G.
Matthias attained a degree in Business Administration and International
Business Studies in a dual system between Merck KGaA and the Darmstadt
Business Academy.
Marco Gadola, Chairman of Medartis, said: "Matthias is an exceptionally
talented and dynamic leader with a track record of delivery, driving growth
and developing winning teams. He brings with him deep expertise in medical
technology as well as strong experience in both developed and developing
markets. I'd like to thank Christoph Brönnimann for his years of great
service and for continuing to lead Medartis until Matthias joins us later
this year, and wish him all the best on his next journey."
Matthias added: "I am delighted to have been appointed as CEO of Medartis.
It is a business with an impressive track record, a leading portfolio, a
talented team and an excellent reputation. I am convinced by the strength of
the business as well as its growth potential and look forward to leading
Medartis into the next phase of development."
Download picture of Matthias Schupp
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss
Exchange: MED / ISIN CH0386200239) is one of the world's leading
manufacturers and suppliers of medical devices for the surgical fixation of
bone fractures in the upper and lower extremities and the
craniomaxillofacial region. Medartis employs more than 830 people in 13
locations and its products are sold in more than 50 countries worldwide.
Medartis is committed to providing surgeons and surgical staff with the most
innovative titanium implants and instruments, as well as world-class
service. For more information, please visit www.medartis.com.
Contact:
Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel
Corporate Communications
Investor contact: investor.relations@medartis.com
Media contact: corporate.communication@medartis.com
+41 61 633 37 36
____________________________________________________________
1941861 09-Jul-2024 CET/CEST
Medartis Holding AG / Key word(s): Personnel
Basel, 9th July 2024 Matthias Schupp appointed as CEO of
Medartis
09-Jul-2024 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this
announcement.
____________________________________________________________
PRESS RELEASE
Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is
solely responsible for the content of this announcement.
Medartis today announced that its Board has appointed Matthias Schupp to the
position of CEO, joining Medartis by the beginning of November. Matthias
will succeed Christoph Brönnimann, who will ensure a seamless transition.
Matthias brings excellent knowledge of the global medical technology sector,
having held various senior leadership roles in Europe and Latin America at
Straumann Group over the last 17 years. During his tenure at Straumann, he
demonstrated a strong ability to perform and transform. In 2014, he assumed
the post of SVP of LATAM at Straumann and in 2015 he also became CEO of
Neodent, steering the LATAM region through ten years of significant growth
and enabling Neodent to flourish into a leading global challenger brand. He
was appointed to the Executive Management Board of Straumann in 2016.
Matthias began his career in 1986 with Merck KGaA and rose through country
management to the position of Regional Manager Latin America and USA. He
moved to Wella in 2000 as Managing Director of the business in Russia and
became Managing Director Professional Care Portugal in 2004, following the
acquisition of Wella by P&G.
Matthias attained a degree in Business Administration and International
Business Studies in a dual system between Merck KGaA and the Darmstadt
Business Academy.
Marco Gadola, Chairman of Medartis, said: "Matthias is an exceptionally
talented and dynamic leader with a track record of delivery, driving growth
and developing winning teams. He brings with him deep expertise in medical
technology as well as strong experience in both developed and developing
markets. I'd like to thank Christoph Brönnimann for his years of great
service and for continuing to lead Medartis until Matthias joins us later
this year, and wish him all the best on his next journey."
Matthias added: "I am delighted to have been appointed as CEO of Medartis.
It is a business with an impressive track record, a leading portfolio, a
talented team and an excellent reputation. I am convinced by the strength of
the business as well as its growth potential and look forward to leading
Medartis into the next phase of development."
Download picture of Matthias Schupp
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss
Exchange: MED / ISIN CH0386200239) is one of the world's leading
manufacturers and suppliers of medical devices for the surgical fixation of
bone fractures in the upper and lower extremities and the
craniomaxillofacial region. Medartis employs more than 830 people in 13
locations and its products are sold in more than 50 countries worldwide.
Medartis is committed to providing surgeons and surgical staff with the most
innovative titanium implants and instruments, as well as world-class
service. For more information, please visit www.medartis.com.
Contact:
Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel
Corporate Communications
Investor contact: investor.relations@medartis.com
Media contact: corporate.communication@medartis.com
+41 61 633 37 36
____________________________________________________________
End of Inside Information
____________________________________________________________
Language: English
Company: Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Switzerland
Phone: +41 61 633 34 34
Fax: +41 61 633 34 00
E-mail: info@medartis.com
Internet: www.medartis.com
ISIN: CH0386200239
Valor: 38620023
Listed: SIX Swiss Exchange
EQS News ID: 1941861
End of Announcement EQS News Service
____________________________________________________________
1941861 09-Jul-2024 CET/CEST
